Radiotherapy for Soft Tissue Sarcomas after Isolated Limb Perfusion and Surgical Resection: Essential for Local Control in All Patients?

Jan P. Deroose, MD1, Jacobus W. A. Burger, MD, PhD1, Albertus N. van Geel, MD, PhD1, Michael A. den Bakker, MD, PhD2, Johannes S. de Jong, MD, PhD1, Alexander M. M. Eggermont, MD, PhD1, and Cornelis Verhoef, MD, PhD1

1Division of Surgical Oncology, Erasmus MC-Daniel den Hoed Cancer Center, Rotterdam, The Netherlands; 2Division of Pathology, Erasmus MC-Daniel den Hoed Cancer Center, EA, Rotterdam, The Netherlands

ABSTRACT

Background. Standard treatment for localized soft tissue sarcoma (STS) is resection plus adjuvant radiotherapy (RTx). In approximately 10% of cases, resection would cause severe loss of function or even require amputation because of the extent of disease. Isolated limb perfusion (ILP) with tumor necrosis factor alpha (TNF-α) and melphalan can achieve regression of the tumor, facilitating limb-saving resection. RTx improves local control but may lead to increased morbidity.

Methods. In our database of over 500 ILPs, 122 patients with unifocal STS were treated by ILP followed by limb-sparing surgery. All included patients were candidates for amputation.

Results. Surgery resulted in 69 R0 resections (57%), and in 53 specimens (43%) resection margins contained microscopic evidence of tumor (R1). Histopathological examination revealed >50% ILP-induced tumor necrosis in 59 cases (48%). RTx was administered in 73 patients (60%). Local recurrence rate was 21% after median follow-up of 31 months (2–182 months). Recurrence was significantly less in patients with >50% ILP-induced necrosis versus ≤50% necrosis (7% vs. 33%, P = 0.001). A similar significant correlation was observed for R0 versus R1 resections (15% vs. 28%, P = 0.04). In 36 patients with R0 resection and >50% necrosis, of whom 21 were spared RTx, no recurrences were observed during follow-up.

Conclusions. In patients with locally advanced primary STS, treated with ILP followed by R0 resection, and with >50% ILP-induced necrosis in the resected specimen, RTx is of no further benefit.

Soft tissue sarcomas (STSs) are a heterogeneous group of rare malignancies. In the USA, 8,680 new cases of STS are diagnosed annually, of which approximately 60% are located in the extremities. STSs are associated with early metastasis and a high disease-specific mortality rate of approximately 50%. Moreover, STS of the extremity is often large at time of presentation, making local resection and tumor control difficult. Local control may require extensive surgery, resulting in loss of limb function or amputation in 10% of cases. Amputation, however, is not associated with prolonged survival, because survival is determined by the occurrence of systemic disease. Since amputation has no beneficial effect on survival, growing interest in limb-salvaging techniques has arisen. Isolated limb perfusion (ILP) is a technique that results in perfusion of a tumor with high concentrations of tumor necrosis factor alpha (TNF-α) and melphalan under hyperthermic conditions. Following introduction of the technique in the early 1990s, Eggermont et al. reported encouraging results in a large European multicenter study. Subsequent studies showed high local response and limb salvage rates and acceptable local and systemic toxicity.

Currently, use of ILP followed by resection and RTx is an established strategy for limb salvage in Europe. Long-term morbidity has been described after ILP. A contributing factor to morbidity is adjuvant RTx. However, whether adjuvant RTx is necessary for all patients treated with ILP remains unclear. The aim of this study is to identify a specific
group of patients in whom adjuvant RTx was of no further benefit for tumor control. All patients in our hospital undergoing ILP for unifocal STS of the extremity followed by local resection were identified. Subsequently, we determined whether patients with STS of the extremity may be spared adjuvant RTx under specific circumstances.

**PATIENTS AND METHODS**

**Patients**

From August 1991 to March 2009, 511 ILPs were performed in our hospital. These 511 cases comprised 168 melanomas, 306 STS, and 37 miscellaneous malignancies (Fig. 1).

ILP was the treatment strategy in 74 cases of multiple STS, while 232 patients were treated for unifocal disease. In this retrospective study we evaluated all 122 consecutive ILPs (in 120 patients) for unifocal STS followed by limb-sparing surgical resection. The minimal tumor–node–metastasis (TNM) stage was IB, while the vast majority of STS was staged as IIB. Liposarcoma was the most common treated type of STS in our study, of which 3 were well differentiated, 2 were dedifferentiated, 7 were pleomorphic, and 16 were of myxoid subtype. Patient characteristics are summarized in Table 1.

**Perfusion**

The technique of ILP with TNF-α and melphalan has been described previously. Briefly, the procedure is performed with patients under general anesthesia. After heparinization, a targeted blood circuit is isolated by clamping and cannulation of the major artery and vein and connection to an oxygenated extracorporeal circuit. A tourniquet compresses collateral vessels and prevents leakage. Using a precordial scintillation probe to detect technetium-labeled albumen, leakage is monitored for the length of the procedure. Patients underwent ILP via axillary (n = 9), brachial (n = 19), iliac (n = 54), femoral (n = 24) or popliteal (n = 16) approach.

**TABLE 1** Patient and tumor characteristics

| Characteristic         | N   | %   |
|------------------------|-----|-----|
| Gender                 |     |     |
| Female                 | 55  | 45.1|
| Male                   | 67  | 54.9|
| Age                    |     |     |
| ≤50 years              | 56  | 45.9|
| >50 years              | 66  | 54.1|
| Size                   |     |     |
| <5 cm                  | 20  | 16.4|
| 5–10 cm                | 34  | 27.9|
| >10 cm                 | 68  | 55.7|
| Trojani grade          |     |     |
| 1                      | 11  | 9.0 |
| 2                      | 31  | 25.4|
| 3                      | 73  | 59.8|
| Missing                | 7   | 5.7 |
| Site                   |     |     |
| Upper arm              | 8   | 6.6 |
| Elbow                  | 5   | 4.1 |
| Lower arm              | 10  | 8.2 |
| Wrist or hand          | 5   | 4.1 |
| Upper leg              | 46  | 37.7|
| Knee                   | 20  | 16.4|
| Lower leg              | 22  | 18.0|
| Ankle or feet          | 6   | 4.9 |
| Histology              |     |     |
| Liposarcoma            | 28  | 23.0|
| Synovial sarcoma       | 24  | 19.7|
| HGPS NOS               | 16  | 13.1|
| Leiomyosarcoma         | 12  | 9.8 |
| Other (16 types)       | 43  | 34.4|
| Primary/recurrent      |     |     |
| Primary                | 102 | 83.6|
| Recurrent              | 20  | 16.4|
| Adjuvant RTx           |     |     |
| No                     | 49  | 40.2|
| Yes                    | 73  | 59.8|

HGPS NOS high-grade pleomorphic sarcoma not otherwise specified

**FIG. 1** Inclusion flow chart
A dose of 1–3 mg (arm) or 1–4 mg (leg) recombinant TNF-α (Boehringer Ingelheim GmbH, Ingelheim/Rhein, Germany) was injected as a bolus once the temperature of the limb reached 38°C. Subsequently, 13 mg/l (arm) or 10 mg/l (leg) melphalan (L-PAM; Alkeran, Burroughs Wellcome Ltd., London, UK) was administered 30 min after the limb temperature reached 38–39.5°C. The median dose of TNF-α administered was 4.0 mg (mean 3.2 mg, range 1–4 mg), while the median dose of melphalan was 75 mg (mean 79.8 mg, range 18–160 mg). Several studies reported successful use of reduced doses of TNF-α in ILP for STS with comparable local recurrence rates and no systemic toxicity.7,8 Thereafter, perfusion was executed with 1 mg TNF-α in the arm and 2 mg in the leg. Consequently, since 2005 the median dose of TNF-α has been 2.0 mg (mean 2.09 mg, range 1–3 mg). After 90 min of perfusion, the limb was washed out with 1 l (arm) to 4 l (iliac perfusion) physiological saline solution and 6% dextran (Macrodex Pharmacia, Uppsala, Sweden). Patients were observed in intensive care unit (ICU) for one night. Median length of hospital stay was 8 days (mean 11 days, range 2–136 days).

Clinical response was defined using clinical findings and magnetic resonance imaging (MRI). Complete response (CR) was defined as complete remission of tumor tissue, while partial response (PR) was defined as 51–99% remission. No change (NC) was defined as 0–50% remission. Clinical evidence of new lesions or growth of the tumor was defined as progressive disease (PD).

**Local Control**

Whenever the response of the tumor to ILP appeared to facilitate local resection without major limb function loss, local resection was attempted. Local resection was performed at median of 84 days (mean 91 days, range 14–260 days) after ILP. Margine status of the resection was defined using the criteria according to Pisters et al.9 In each surgical specimen the peripheral margins were inked. A microscopically positive (R1) margin was defined as unequivocal tumor extension to the inked margin on permanent section. Cases in which tumor was close to but did not reach the inked margin were considered to have microscopically negative margins (R0). The percentage of the tumor that was necrotic due to ILP was estimated by the pathologist by macroscopic inspection and microscopic confirmation. Two categories were defined: 51–99% necrosis of the tumor and 0–50% necrosis of the tumor.

**Radiotherapy**

Adjuvant RTx was administered to 73 (60%) patients, while 49 (40%) patients did not receive RTx. Like all other decisions concerning STS, decisions on the subject of adjuvant RTx were made in a multidisciplinary board containing a surgical oncologist, a medical oncologist, a radiation oncologist, a pathologist, and a radiologist. Before 1998, there was little evidence that adjuvant RTx was beneficial after local resection of STS. Since Olieman et al.10 reported improved outcome after adjuvant RTx in 1998, our center has administered significantly more RTx (\(P = 0.04\)). Reasons for refraining from administering adjuvant RTx after 1998 are summarized in Table 2.

**RESULTS**

**Clinical Response**

Clinical response after ILP was complete in five cases (4%). PR was obtained in 80 patients (66%), NC in 35 patients (29%), and PD in 1 patient (1%). Clinical response was not assessed in one patient (1%) for unknown reason.

**Local Control**

Results are summarized in Table 3. Local resection of the STS resulted in R0 resection in 69 patients (57%), while 53 (43%) patients had R1/R2 resection. The overall local recurrence rate was 21% (25 patients) after median follow-up of 31 months (mean 48 months, range 2–182 months); 5-year recurrence-free survival (RFS) was 75% (±5% standard error, SE). If recurrence occurred, median time to recurrence was 15 months (mean 27 months, range 3–170 months). After R0 resection, 5-year RFS was 80%, while patients with R1 resection had 5-year RFS of 72%. This difference reached significance (\(P = 0.04\), Fig. 2). The local recurrence rate was 15% in the R0 group (10 patients), while the R1 group had a local recurrence rate of 28% (15 patients). In 13 cases (11%), amputation, after limb-saving resection, was deemed necessary during follow-up. Median time between limb-saving resection and amputation was 29 months (mean 25 months, range 2–60 months). Consequently, the limb salvage rate was 89%.

**TABLE 2 Reasons for no RTx after 1998**

| Reason          | \(N\) | %  |
|-----------------|------|----|
| Systemic disease| 8    | 40 |
| Joint/hand/foot | 3    | 15 |
| Age/comorbidity | 2    | 10 |
| Refused by patient | 1 | 5  |
| Reason not specified | 6 | 30 |
| Total           | 49   | 100.0 |

---

RTx for STS after ILP and Surgical Resection 323
Histopathological examination of the resection specimens revealed 50% ILP-induced tumor necrosis in 59 cases (48%). In 63 (52%) cases the response to ILP was 50% or less. Patients with 50% necrosis in specimen after resection had 5-year RFS of 92%, while patients with >50% necrosis had 5-year RFS of 61%. As can be seen in Fig. 3, this difference was significant (P = 0.001).

In the group with >50% necrosis of the tumor, the local recurrence rate was 7% (4 cases), compared with 33% (21 cases) in the group with ≤50% tumor necrosis. None of the patients were treated with adjuvant systemic chemotherapy or any other treatment modality in the time interval between ILP and resection. Combining these results we could define a group of 43 patients (35%) with R0 resection and >50% tumor necrosis, with a single case of local recurrence. This concerned a patient who was treated for local recurrence. This female, aged 44 years, had no signs of residual vital tumor in the resected specimen. Since the tumor had been small and difficult to locate preoperatively, the completeness of the resection was deemed doubtful. Therefore, RTx was proposed, but refused by the patient. In retrospect, we believe that the tumor was not resected during surgery.

None of the patients with R0 resection and >50% necrosis who were treated for primary STS (n = 36) developed local recurrence. Patients with R0 resection but less than 50% necrosis of tumor (n = 26) showed recurrence in nine cases (35%).

The local recurrence rate for patients treated with adjuvant RTx was 23%, while patients not treated with RTx had local recurrence in eight cases (16%). Whether patients with R0 resection had RTx was not based on main tumor characteristics (Table 4).

**DISCUSSION**

Our results suggest that patients with primary and unifocal STS of the extremity, in whom R0 resection is achieved after successful ILP (induction of >50% necrosis), may not benefit from adjuvant RTx. In these patients, the recurrence rate was 0%. Patients treated for recurrence

---

**TABLE 3** Results for all STS

| R Histology (%) | N | Recurrence | Recurrence rate (%) |
|-----------------|---|------------|---------------------|
| No RTx          |   |            |                     |
| R0 ≤50          | 7 | 1          | 14.3                |
| R0 >50          | 28| 1<sup>a</sup> | 3.6                 |
| R1 ≤50          | 8 | 4          | 50.0                |
| R1 >50          | 6 | 2          | 33.3                |
| Total           | 49| 8          | 16.3                |
| RTx             |   |            |                     |
| R0 ≤50          | 19| 8          | 42.1                |
| R0 >50          | 15| 0          | 0.0                 |
| R1 ≤50          | 29| 8          | 27.6                |
| R1 >50          | 10| 1          | 10.0                |
| Total           | 73| 17         | 23.3                |
| Total           | 122| 25       | 20.5                |

<sup>a</sup> One patient with local recurrence of a secondary diagnosed STS

**FIG. 2** Local recurrence versus R0/R1

**FIG. 3** Local recurrence versus histopathological response

**Nr at Risk**

| R0 | 66 | 57 | 39 | 34 | 27 | 20 |
|----|----|----|----|----|----|----|
| R1 | 53 | 34 | 22 | 17 | 14 | 11 |
| Total | 122 | 91 | 61 | 51 | 41 | 31 |

**Log rank: p = 0.04**

**Nr at Risk**

| > 50% | 63 | 45 | 30 | 25 | 20 | 16 |
| ≤ 50% | 59 | 46 | 31 | 26 | 21 | 15 |
| Total | 122 | 91 | 61 | 51 | 41 | 31 |

**Log rank: p = 0.001**

**Months**

| 0 | 12 | 24 | 36 | 48 | 60 |
|---|----|----|----|----|----|
| 1.0 | 0.8 | 0.6 | 0.4 | 0.2 |
| Log rank: p = 0.04 |

| Recurrence-free survival |
|---------------------------|
| 1.0 | 0.8 | 0.6 | 0.4 | 0.2 |

| Months |
|-------|
| 0 | 12 | 24 | 36 | 48 | 60 |
| Log rank: p = 0.001 |

| Nr at Risk |
| R0 | 66 | 57 | 39 | 34 | 27 | 20 |
| R1 | 53 | 34 | 22 | 17 | 14 | 11 |
| Total | 122 | 91 | 61 | 51 | 41 | 31 |

**Log rank: p = 0.04**
of STS (n = 7), who had R0 resection and >50% tumor necrosis, showed local recurrence in one case.

The overall local recurrence rate in our series was 21%, which is in accordance with several other studies describing ILP as a limb-saving strategy for STS (11–34%), while reported recurrence rates for primarily resectable STS range from 10 to 27%.5,7,10–18

A CR rate of 4% seems low compared with the rate of 28% in the multicenter trial published by Eggemann et al. or in comparison with the latest studies of Bonvalot et al. (30%; n = 100), Grabellus et al. (15%; n = 47), and Pennachioli et al. (41%; n = 88).7,14–16 The discordance is due to selection bias, since we only included patients with limb-sparing surgery after ILP. The vast majority of patients with MRI-proven CR were not considered for resection and had clinical follow-up for 10 years. Another bias was the exclusion of multifocal tumors in general (Lev–Chelouche, CR = 38, n = 53) or Stewart–Treves lymphangiosarcoma (Lans et al., CR = 56%; n = 16), which are known to respond well to ILP.19,20 With the introduction of the use of TNF-α in ILP there was a substantial improvement in treatment for nonresectable extremity STS.4,5,12,21,22 Nowadays ILP with delayed resection is an established strategy for limb salvage in Europe. Median time span between resection and ILP was 84 days, which was within the range of previous reports (42–117 days).22,23 Completeness of resection is an important prognostic factor for local recurrence.14,17,18,24–26 After R0 or R1 resection in patients with over 50% tumor necrosis, a local recurrence rate of only 7% was observed. Of patients with ≤50% necrosis in resection specimen, 33% had recurrence. This highly significant difference suggests that the degree of ILP-mediated tumor necrosis might be an even stronger prognostic factor for local recurrence and supports the findings of Grabellus et al.14 that improved margin status is achieved after ILP. In patients with R1 resection with >50% necrosis, 19% local recurrence was observed. This is a notable improvement in comparison with the large analysis (n = 1,041) of Pisters et al. who reported a local recurrence rate of 40% for R1 resection of extremity STS without ILP.18 Considering the larger proportion of large tumors (>10 cm; 25 vs. 56%) in our series, this result is more remarkable.

It could be argued that determining the degree of necrosis may not necessarily reflect a therapy effect but may be inherent tumor necrosis. Furthermore, macroscopic evaluation is a subjective and therefore imprecise factor. Considering the fact that tumor necrosis in untreated STS is an independent unfavorable prognostic factor, it may be assumed that the necrosis observed in ILP-treated sarcomas is indeed therapy related and prognostically relevant. Second, considering the broad categories defined for tumor necrosis in grading systems (0, <50, and >50%) it is highly unlikely that the degree of necrosis in single cases falls near the cutoff point. Furthermore, in our experience the pattern of necrosis in ILP-treated sarcomas, consisting of large confluent areas of necrosis, is different from the patch pattern of necrosis seen as spontaneous necrosis in untreated sarcomas. Finally, the MRIs that were performed before ILP showed central necrosis in only 7 (12%) of 59 cases with >50% ILP-induced necrosis.

The value of adjuvant RTx after ILP and resection is still unclear. The beneficial effect of irradiation in limb-sparing surgery for STS was first demonstrated by Rosenberg et al.2 Despite reporting a significant decrease in STS local recurrence after irradiation therapy, Yang et al.27 concluded that, in selected patients with low risk for recurrence, irradiation should not be considered because of important lifetime risk for complications. Other studies claimed that adjuvant RTx in all cases had a significant positive influence in obtaining local control.10,23

Complications of RTx should not be underestimated. Hoven-Gonderie et al.28 reported that two-thirds of all patients experienced serious late toxic problems after combined treatment for STS. Major problems with wound healing and continuous wound infections (8–14%) are described in literature.29,30 Vascular damage (4–14%) is a common long-term complication of RTx.6,30,31 Kalman et al.32 described four cases of long-term vascular side-effects in the axillary artery after mastectomy with adjuvant RTx, 10–27 years after treatment. RTx may cause neuropathy, especially when a boost is given.28,33

**TABLE 4 R0 resection ± RTx**

| Size         | RTx              |
|--------------|------------------|
|              | No | Yes |
| <5 cm        | 7  | 5   |
| 5–10 cm      | 11 | 8   |
| >10 cm       | 17 | 21  |
| Trojani grade|     |     |
| 1            | 5  |
| 2            | 14 | 9   |
| 3            | 16 | 22  |
| Missing      | 0  | 2   |
| Histology    |     |     |
| Liposarcoma  | 9  | 7   |
| Synovial sarcoma | 4  | 8   |
| HGPS NOS     | 7  | 3   |
| Leiomyosarcoma| 4  | 2   |
| Other (16 types) | 11 | 14  |
| Primary/recurrent |     |     |
| Primary      | 26 | 29  |
| Recurrent    | 9  | 5   |

*HGPS NOS high-grade pleomorphic sarcoma not otherwise specified*
Although radiation is effective in improving local control, several studies suggest that, after margin-free resection, a subset of patients do not benefit from RTx.\textsuperscript{1,4,34,35} In a prospective study, Pisters et al.\textsuperscript{9} reported that patients with T1, R0-resected STS have acceptable long-term local control and may be spared the short- and long-term toxicity of RTx.

In our series, patients were not randomized for adjuvant RTx, so the conclusions based on our findings have to be read with caution. Furthermore, with 36 patients in 18 years, the defined group that can be spared RTx is relatively small. Further studies should be performed to confirm these findings. Nevertheless, our results suggest that patients with R0 resection combined with >50% ILP-induced necrosis may be spared adjuvant RTx. The benefit of adjuvant RTx after ILP followed by limb-sparing surgery for this subset of patients seems limited. The added morbidity, the lack of survival benefit, and the limited effect on local recurrence should be discussed with these patients.

**OPEN ACCESS** This article is distributed under the terms of the Creative Commons Attribution Noncommercial License which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author(s) and source are credited.

**REFERENCES**

1. Cormier JN, Pollock RE. Soft tissue sarcomas. CA Cancer J Clin. 2004;54(2):94–109.
2. Rosenberg SA, Tepper J, Glatstein E, et al. The treatment of soft-tissue sarcomas of the extremities: prospective randomized evaluations of (1) limb-sparing surgery plus radiation therapy compared with amputation and (2) the role of adjuvant chemotherapy. Ann Surg. 1982;196(3):305–15.
3. Williard WC, Hajdu SI, Casper ES, Brennan MF. Comparison of amputation with limb-sparing operations for adult soft tissue sarcoma of the extremity. Ann Surg. 1992;215(3):269–75.
4. Eggermont AM, Schraffordt Koops H, Klausner JM, et al. Isolated limb perfusion with high-dose tumor necrosis factor-alpha for locally advanced extremity soft tissue sarcomas. Cancer Treat Res. 1997;91:189–203.
5. Grunhagen DJ, de Wilt JH, Graveland WJ, et al. Outcome and prognostic factor analysis of 217 consecutive isolated limb perfusions with tumor necrosis factor-alpha and melphalan for limb-threatening soft tissue sarcoma. Cancer. 2006;106(8):1776–84.
6. van Ginkel RJ, Thijssens JM, Pras E, et al. Isolated limb perfusion with tumor necrosis factor alpha and melphalan for locally advanced soft tissue sarcoma: three time periods at risk for amputation. Ann Surg Oncol. 2007;14(4):1499–506.
7. Bonvalot S, Rimareix F, Cauzeret S, et al. Hyperthermic isolated limb perfusion in locally advanced soft tissue sarcoma and progressive desmoid-type fibromatosis with TNF 1 mg and melphalan (T1-M HILP) is safe and efficient. Ann Surg Oncol. 2009;16(2):3350–7.
8. Grunhagen DJ, de Wilt JH, van Geel AN, et al. TNF dose reduction in isolated limb perfusion. Eur J Surg Oncol. 2005;31(9):1011–9.
9. Pisters PW, Pollock RE, Lewis VO, et al. Long-term results of prospective trial of surgery alone with selective use of radiation for patients with T1 extremity and trunk soft tissue sarcomas. Ann Surg. 2007;246(4):675–81; discussion 681–2.
10. Olieman AF, Pras E, van Ginkel RJ, et al. Feasibility and efficacy of external beam radiotherapy after hyperthermic isolated limb perfusion with TNF-alpha and melphalan for limb-saving treatment in locally advanced extremity soft-tissue sarcoma. Int J Radiat Oncol Biol Phys. 1998;40(4):807–14.
11. Cherix S, Speiser M, Matter M, et al. Isolated limb perfusion with tumor necrosis factor and melphalan for non-resectable soft tissue sarcomas: long-term results on efficacy and limb salvage in a selected group of patients. J Surg Oncol. 2008;98(3):148–55.
12. Gutman M, Inbar M, Lev-Shlush D, et al. High dose tumor necrosis factor-alpha and melphalan administered via isolated limb perfusion for advanced limb soft tissue sarcoma results in a >90% response rate and limb preservation. Cancer. 1997;79(6):1129–37.
13. Vrouwenraets BC, in’t Veld GJ, Nieweg OE, et al. Long-term functional morbidity after mild hyperthermic isolated limb perfusion with melphalan. Eur J Surg Oncol. 1999;25(5):503–8.
14. Grabellus F, Kraft C, Sheu SY, et al. Evaluation of 47 soft tissue sarcoma resection specimens after isolated limb perfusion with TNF-alpha and melphalan: histologically characterized improved margins correlate with absence of recurrences. Ann Surg Oncol. 2009;16(3):676–86.
15. Eggermont AM, Schraffordt Koops H, Klausner JM, et al. Isolated limb perfusion with tumor necrosis factor and melphalan for limb salvage in 186 patients with locally advanced soft tissue extremity sarcomas. The cumulative multicenter European experience. Ann Surg. 1996;224(6):756–64; discussion 764–5.
16. Pennacchioni E, Deraco M, Mariani L, et al. Advanced extremity soft tissue sarcoma: prognostic effect of isolated limb perfusion in a series of 88 patients treated at a single institution. Ann Surg Oncol. 2007;14(2):553–9.
17. Coindre JM, Terrier P, Bui NB, et al. Prognostic factors in adult patients with locally controlled soft tissue sarcoma. A study of 546 patients from the French Federation of Cancer Centers Sarcoma Group. J Clin Oncol. 1996;14(3):869–77.
18. Pisters PW, Leung DH, Woodruff J, et al. Analysis of prognostic factors in 1,041 patients with localized soft tissue sarcomas of the extremities. J Clin Oncol. 1996;14(5):1679–89.
19. Lev-Chelouche D, Abu-Abied S, Kollander Y, et al. Multifocal soft tissue sarcoma: limb salvage following hyperthermic isolated limb perfusion with high-dose tumor necrosis factor and melphalan. J Surg Oncol. 1999;70(3):185–9.
20. Lans TE, de Wilt JH, van Geel AN, Eggermont AM. Isolated limb perfusion with tumor necrosis factor and melphalan for nonresectable »Stewart-Treves« lymphangiosarcoma. Ann Surg Oncol. 2002;9(10):1004–9.
21. Lejeune FJ, Pujol N, Lienard D, et al. Limb salvage by neoadjuvant isolated perfusion with TNFAlphalpha and melphalan for nonresectable soft tissue sarcoma of the extremities. Eur J Surg Oncol. 2000;26(7):669–78.
22. Noorda EM, Vrouwenraets BC, Nieweg OE, et al. Isolated limb perfusion with tumor necrosis factor-alpha and melphalan for patients with unresectable soft tissue sarcoma of the extremities. Cancer. 2003;98(7):1483–90.
23. Thijssens JM, van Ginkel RJ, Pras E, et al. Isolated limb perfusion with tumor necrosis factor alpha and melphalan for locally advanced soft tissue sarcoma: the value of adjuvant radiotherapy. Ann Surg Oncol. 2006;13(4):S18–24.
24. Lewis JJ, Leung DH, Heslin M, et al. Association of local recurrence with subsequent survival in extremity soft tissue sarcoma. J Clin Oncol. 1997;15(2):646–52.
25. Stojadinovic A, Leung DH, Allen P, et al. Primary adult soft tissue sarcoma: time-dependent influence of prognostic variables. J Clin Oncol. 2002;20(21):4344–52.
26. Trovik CS, Bauer HC, Alvegard TA, et al. Surgical margins, local recurrence and metastasis in soft tissue sarcomas: 559 surgically-treated patients from the Scandinavian Sarcoma Group Register. *Eur J Cancer*. 2000;36(6):710–6.
27. Yang JC, Chang AE, Baker AR, et al. Randomized prospective study of the benefit of adjuvant radiation therapy in the treatment of soft tissue sarcomas of the extremity. *J Clin Oncol*. 1998;16(1):197–203.
28. Hoven-Gondrie ML, Thijssens KM, Geertzen JH, et al. Isolated limb perfusion and external beam radiotherapy for soft tissue sarcomas of the extremity: long-term effects on normal tissue according to the LENT-SOMA scoring system. *Ann Surg Oncol*. 2008;15(5):1502–10.
29. Ormsby MV, Hilaris BS, Nori D, Brennan MF. Wound complications of adjuvant radiation therapy in patients with soft-tissue sarcomas. *Ann Surg*. 1989;210(1):93–9.
30. Vrouenraets BC, Keus RB, Nieweg OE, Kroon BB. Complications of combined radiotherapy and isolated limb perfusion with tumor necrosis factor alpha +/- interferon gamma and melphalan in patients with irresectable soft tissue tumors. *J Surg Oncol*. 1997;65(2):88–94.
31. Hoven-Gondrie ML, Thijssens KM, Van den Dungen JJ, et al. Long-term locoregional vascular morbidity after isolated limb perfusion and external-beam radiotherapy for soft tissue sarcoma of the extremity. *Ann Surg Oncol*. 2007;14(7):2105–12.
32. Kalman PG, Lipton IH, Provan JL, et al. Radiation damage to large arteries. *Can J Surg*. 1983;26(1):88–91.
33. Milbeo Y, Kantor G, Laharie H, et al. Adjuvant radiation therapy for soft tissue sarcoma of the extremities: analysis of local control according to volume and dose. *Cancer Radiother*. 2005;9(5):293–303.
34. Baldini EH, Goldberg J, Jenner C, et al. Long-term outcomes after function-sparing surgery without radiotherapy for soft tissue sarcoma of the extremities and trunk. *J Clin Oncol*. 1999;17(10):3252–9.
35. Khanfir K, Alzieu L, Terrier P, et al. Does adjuvant radiation therapy increase loco-regional control after optimal resection of soft-tissue sarcoma of the extremities? *Eur J Cancer*. 2003;39(13):1872–80.